Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 16,542 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Connective Tissue Disease Clear all

Conditions: Melanoma (Skin)
Interventions: aldesleukin, sargramostim, adjuvant therapy; Biological · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Melanoma
Interventions: GM-CSF, Standard of Care; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Advanced Solid Tumor
Interventions: STX-003, KEYTRUDA®; Biological
Lead sponsor: Strand Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Scottsdale, Arizona • Boston, Massachusetts • Nashville, Tennessee

Conditions: Melanoma (Skin), Non-melanomatous Skin Cancer
Interventions: educational intervention, internet-based intervention; Other
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years and older
Enrollment: 4,550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2004
U.S. locations: 5
States / cities: San Diego, California • Wichita, Kansas • Columbus, Ohio + 2 more

Conditions: Pressure Injury, Pressure Ulcer
Interventions: LAL, Non-LAL; Device
Lead sponsor: David Brienza; Other
Eligibility: 18 Years and older
Enrollment: 457 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Cancer, Fatigue, Lymphedema
Interventions: expressive writing; Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 21 Years to 80 Years · Female only
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 3
States / cities: Nashville, Tennessee

Conditions: Lymphoma
Interventions: No intervention; Other
Lead sponsor: Centocor Ortho Biotech Services, L.L.C.; Industry
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 3
States / cities: Highland Park, Illinois • Wichita, Kansas • Albany, New York

Conditions: Breast Cancer
Interventions: Paclitaxel, Trastuzumab, Neratinib, Doxorubicin, Cyclophosphamide; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 30
States / cities: Loma Linda, California • San Diego, California • Denver, Colorado + 25 more

Conditions: Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
Interventions: KB803, Placebo; Biological · Drug
Lead sponsor: Krystal Biotech, Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Rancho Santa Margarita, California • Coral Gables, Florida • Worcester, Massachusetts + 2 more

Conditions: Breast Neoplasms
Interventions: Physical activity; Behavioral
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Rheumatoid Arthritis
Interventions: Natrunix, Placebo; Drug
Lead sponsor: XBiotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 26
States / cities: Covina, California • Encino, California • Rancho Mirage, California + 19 more

Conditions: Ovarian Neoplasms, Colorectal Neoplasms, Melanoma, Small Cell Lung Cancer, Liposarcoma
Interventions: Ionizing radiation (IR) therapy, Ionizing radiation (IR); Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 19 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Port-wine Stain
Interventions: Photo Acoustic Microscopy and Optical Coherence tomography; Device
Lead sponsor: University of California, Irvine; Other
Eligibility: Not listed
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Irvine, California

Conditions: Acne Inversa
Interventions: PF-06650833, PF-06700841, PF-06826647, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 63
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Fremont, California + 42 more

Conditions: Breast Cancer, Breast Cancer in Young Women, Breast Cancer in Women With a Strong Family History
Interventions: Targeted, Enhanced Tailored; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 20 Years to 64 Years · Female only
Enrollment: 1,290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Lansing, Michigan

Conditions: Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis
Interventions: Elenestinib, Placebo; Drug
Lead sponsor: Blueprint Medicines Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 15
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 12 more

Conditions: Generalized Lipodystrophy
Interventions: Placebo, Low-Dose REGN4461, High-dose REGN4461; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 3
States / cities: Bethesda, Maryland • Ann Arbor, Michigan • Dallas, Texas

Conditions: Breast Cancer
Interventions: Digital Mammography, Low Osmolar Contrast Material, 300-399 Mg/Ml Iodine Concentration, Per Ml; Procedure · Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Malignant Melanoma
Interventions: Denileukin diftitox; Drug
Lead sponsor: James Graham Brown Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Chronic Spontaneous Urticaria
Interventions: Dupilumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 9
States / cities: Coral Gables, Florida • Boise, Idaho • St Louis, Missouri + 6 more

Conditions: Acne Vulgaris
Interventions: IDP-126 Gel, IDP-126 Vehicle Gel, Epiduo® Forte Gel; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 12 Years to 99 Years
Enrollment: 686 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 34
States / cities: Bryant, Arkansas • Rogers, Arkansas • Fremont, California + 27 more

Conditions: Atopic Dermatitis
Interventions: Barzolvolimab, Matching placebo; Biological · Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 33
States / cities: Birmingham, Alabama • Beverly Hills, California • Burbank, California + 28 more

Conditions: Breast Cancer
Interventions: PTK787, Trastuzumab; Drug
Lead sponsor: Hoosier Cancer Research Network; Other
Eligibility: 18 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 8
States / cities: Elkhart, Indiana • Fort Wayne, Indiana • Goshen, Indiana + 5 more

Conditions: Diabetic Foot Ulcer (DFU), Ulcer Foot, Diabetic Foot, Foot Ulcer
Interventions: Standard of Care, Revita, Relese, Cogenex, Enverse; Other
Lead sponsor: StimLabs; Industry
Eligibility: 18 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: Omaha, Nebraska • Tulsa, Oklahoma • Jefferson Hills, Pennsylvania + 2 more

Search by objective public record fields.

Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma

Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma

Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

Computer-Based Continuing Education for Doctors in Examination and Counseling of Patients on Skin Cancer or Weight Control

An RCT on Support Surfaces for Pressure Ulcer Prevention

Expressive Writing in Improving Quality of Life in Patients With Breast Cancer and Lymphedema

An Observational Study of Lymphoma in Patients With Rheumatoid Arthritis or Crohn's Disease.

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa

Exercise in Women at Risk for Breast Cancer

Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis

An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation

Evaluate the Port-wine Stain Birthmark Treatment Before and After Pulsed Dye Laser Treatment

A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa

Interventions to Increase Screening by Breast Cancer Survivors and Their High Risk Female Relatives

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy

Performance of Contrast-Enhanced Spectral Mammography to Assess Neoadjuvant Chemotherapy Response (CEDM)

Phase II Trial of Ontak With Metastatic Melanoma

A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)

Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel

A Study of Barzolvolimab in Patients With Atopic Dermatitis

PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer

Modified Platform Trial Assessing Multiple CAMPs and SOC vs SOC Alone in the Treatment of Hard-to-Heal DFUs